Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN has announced the completion of its acquisition of Verogen for $150 million in cash, enhancing its position in the next-generation sequencing (NGS) market for forensic applications. This acquisition follows a partnership that began in June 2021 and is expected to generate $20 million in sales from Verogen’s offerings in 2023. However, it will be dilutive to QIAGEN’s adjusted EPS by about $0.03 per share for 2023. The integration of Verogen’s technology is anticipated to broaden QIAGEN’s capabilities in human identification and forensic investigations.
QIAGEN has entered an exclusive partnership with Helix to enhance companion diagnostics for hereditary diseases. The collaboration will utilize Helix's laboratory platform and QIAGEN's regulatory expertise to accelerate patient recruitment and real-world evidence generation. This partnership aims to provide innovative diagnostic solutions for neuro-degenerative, cardiovascular, and autoimmune diseases, benefiting hundreds of millions globally. QIAGEN will exclusively market Helix's companion diagnostic services in the U.S., leveraging their extensive network and experience in precision medicine.
Helix and QIAGEN have announced a global strategic partnership to co-develop companion diagnostics for hereditary diseases. This collaboration will utilize the Helix Laboratory Platform alongside QIAGEN's diagnostic technologies. The partnership aims to tackle significant health issues, such as neuro-degenerative and cardiovascular diseases. Helix's platform is the first FDA-approved Class II diagnostic system, enhancing patient recruitment for clinical trials. The two companies plan to reveal further details at the upcoming JPMorgan Health Care Conference in San Francisco.
QIAGEN has received FDA approval for its therascreen KRAS RGQ PCR kit as a companion diagnostic for KRAZATI (adagrasib), targeting non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. This marks the 4th approval of the kit, expanding treatment options for an underserved population with high unmet needs. The kit is designed for fast, cost-effective testing, allowing for timely and informed treatment decisions. QIAGEN's advancements reflect strong collaboration with Mirati Therapeutics and underscore their leadership in RAS companion diagnostics.
QIAGEN N.V. (NYSE: QGEN) reported Q3 2022 net sales of
QIAGEN N.V. (NYSE: QGEN) announced it will release its third-quarter 2022 results on November 7 at 22:05 Frankfurt time. A conference call for discussion will occur the following day, November 8, at 15:00 Frankfurt time. Participants can join via a callback registration, phone dial-in, or by accessing an audio webcast. QIAGEN, based in the Netherlands, provides solutions enabling molecular insights from biological samples, supporting over 500,000 customers globally.
IGI Inex Holding has announced its strategic investment in quantumrock, a Munich-based AI and machine learning asset management company. This investment positions IGI with a relevant share based on quantumrock's valuation of €30 million, with options to increase its stake over time. The partnership aims to create innovative investment products that offer loss protection features desired by institutional investors. Quantumrock plans to leverage IGI’s precious stone holdings to develop unique investment strategies, enhancing their asset-backed investment product offerings.
QIAGEN N.V. (NYSE: QGEN) has expanded its NeuMoDx assay menu with new CE-IVD certified tests for Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6), bringing the total to 16 assays. These tests enhance monitoring for immunocompromised organ transplant patients, addressing significant postoperative risks. The company is also developing a multiplex assay for monkeypox and a new dual-target SARS-CoV-2 test, aimed at improving respiratory disease diagnostics. QIAGEN's automated solutions streamline workflows and improve lab efficiency.
QIAGEN has signed a collaboration agreement with Neuron23 to develop a companion diagnostic for a LRRK2 inhibitor aimed at treating Parkinson’s disease. This assay will utilize next-generation sequencing (NGS) technology to identify biomarkers predicting patient responsiveness. The collaboration enhances QIAGEN's NGS testing portfolio, expanding its precision medicine applications into neurology. Neuron23's LRRK2 inhibitor is in late-stage preclinical development, and this partnership is part of QIAGEN's strategy to leverage its expertise in molecular testing to support groundbreaking therapies.
Neuron23 and QIAGEN announced a collaboration on September 14, 2022, to develop the first companion diagnostic for Neuron23’s LRRK2 inhibitor aimed at treating Parkinson’s disease. Under the agreement, QIAGEN will create a clinical trial assay detecting biomarkers that predict patient responsiveness to the drug. This assay will be integrated into a next-generation sequencing workflow, facilitating concurrent submissions for FDA approval of both the diagnostic test and drug application.
The collaboration highlights the potential of precision medicine in neurodegenerative diseases.
FAQ
What is the current stock price of Qiagen (QGEN)?
What is the market cap of Qiagen (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
